The leading representative office of defined VC is situated in the Copenhagen. The fund was located in Europe if to be more exact in Denmark.
Among the various public portfolio startups of the fund, we may underline F2G, Anergis, OxThera Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Denmark. Among the most successful fund investment fields, there are Electronics, Medical. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 of the founder, the chance for it to get the investment is meager.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. Comparing to the other companies, this Sunstone Life Science Ventures performs on 2 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2014.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Sunstone Life Science Ventures, startups are often financed by Novo Seeds, Novo Holdings, Novartis Venture Fund. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Forbion Capital Partners, Omega Funds. In the next rounds fund is usually obtained by Novo Holdings, Atlas Venture, Aescap Venture.
The overall number of key employees were 6.
Company | Industry | Round | Round Size | Date | Investors | Location |
Egalet | 11 Feb 2014 | United States, Radnor Township | ||||
Egalet | 14M | 07 May 2012 | United States, Radnor Township | |||
Orphazyme | 80M | 24 Nov 2017 | Denmark, Copenhagen | |||
Anergis | 5M | 04 Apr 2016 | Switzerland, Epalinges | |||
Anergis | 20M | 28 Mar 2011 | Switzerland, Epalinges | |||
Orphazyme | 14 Feb 2011 | Denmark, Copenhagen | ||||
Biomonitor | 4M | 30 Jun 2008 | Denmark, Copenhagen | |||
Pulmologix | 9M | 18 Sep 2014 | Sweden, Stockholm | |||
Cantargia | 1000K | 05 Jul 2013 | Sweden, Lund | |||
Forendo Pharma | 5M | 18 Jul 2019 | Finland, Turku |
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.